ERBB2 and breast carcinoma: As shown in Fig. 8a, BT474 and SKBR3 cell viability was drastically reduced in lapatinib + ganetespib-treated cells as compared to lapatinib treatment or ganetespib treatment alone, indicating synergistic inhibitory effects on ErbB2+ breast cancer cell viability.